Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- Accera Inc. is presenting topline data today from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Consistent with the findings of Accera's Phase IIa study, subjects who did not have the ApoE4 genotype-a known genetic risk factor that occurs in half of all AD patients-responded particularly well to treatment, as reflected in statistically significant improvement in AD Assessment Scale- Cognitive (ADAS-Cog) scores.

Subjects underwent pharmacogenomic analysis for a variety of genetic markers and were evaluated through a battery of neuropsychometric tests at Day 0, 45, and 90. Compared to the placebo group, the ADAS-Cog scores of the AC- 1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01), and statistically significant improvement was seen in just 45 days.

Interestingly, ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5 point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease. "The profound effect we see in the population without the ApoE4 risk factor supports the findings of an earlier study linking efficacy to a certain pharmacogenomic profile," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and glucose metabolism."

Regardless of genotype, subjects treated with AC-1202 showed a trend toward improvement (p=.072), suggesting the com
'"/>




Page: 1 2 3

Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Aesthetic Lasers and ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America ... 2020 Summary GlobalData,s new report, "North ... to 2020", provides key market data on the ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... 8, 2012 Stereotaxis, Inc. (NASDAQ: STXS ) ... 31, 2012.  Management Comments ... Stereotaxis, said, "In the first quarter, we continued to capitalize ... Solution and robust utilization, realizing a 20% improvement in revenue ...
... WASHINGTON, May 8, 2012  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the development and commercialization of products for the treatment ... operational results for the first quarter ended March 31, ... tasimelteon Non-24-Hour Disorder (Non-24) program continues to advance towards ...
Cached Medicine Technology:Stereotaxis Reports Improved First Quarter 2012 Financial Results 2Stereotaxis Reports Improved First Quarter 2012 Financial Results 3Stereotaxis Reports Improved First Quarter 2012 Financial Results 4Stereotaxis Reports Improved First Quarter 2012 Financial Results 5Stereotaxis Reports Improved First Quarter 2012 Financial Results 6Stereotaxis Reports Improved First Quarter 2012 Financial Results 7Stereotaxis Reports Improved First Quarter 2012 Financial Results 8Vanda Pharmaceuticals Reports First Quarter 2012 Results 2Vanda Pharmaceuticals Reports First Quarter 2012 Results 3Vanda Pharmaceuticals Reports First Quarter 2012 Results 4Vanda Pharmaceuticals Reports First Quarter 2012 Results 5Vanda Pharmaceuticals Reports First Quarter 2012 Results 6Vanda Pharmaceuticals Reports First Quarter 2012 Results 7Vanda Pharmaceuticals Reports First Quarter 2012 Results 8Vanda Pharmaceuticals Reports First Quarter 2012 Results 9
(Date:8/30/2014)... Midland, TX (PRWEB) August 30, 2014 ... Quotes Pros company to introduce better prices to consumers ... insurance plans can be found when using the open ... The national lookup system available to use this year ... for insurance based on general location and not from ...
(Date:8/30/2014)... 30, 2014 Daily Gossip magazine reveals ... anxiety and panic attacks under control with a simple ... review describes this new method as an anxiety ... attacks and overcome general anxiety related disorders. , ... the fact that it can be accessed by users ...
(Date:8/30/2014)... 30, 2014 Ticket Down ... Tennis Championship tickets in NYC. This popular ... US-OPEN-2014 for all day session, evening session, courtside seats, ... for this prestigious Grand Slam Tournament. , The 2014 ... , US Open Tennis Championship: Men's/Women's 3rd Round - ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, has ... Dementia, and Memory Loss . , Country singer Glen Campbell, ... the Alzheimer’s, inspired Seniors Guide writers to review the trailer ... out on October 14, 2014, shows a glimpse of Glen ... – which inspires a final tour from the musician while ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... (Wake Forest University Baptist Medical Center) Parkland ... Hospitals and ClinicsUniversity of Wisconsin Hospital & ... the second year, the University HealthSystem Consortium ... for demonstrating excellence in supply chain management ...
... NEW YORK, March 9 The American Heart Association and,Macy,s ... designed to support Latinas in pursuit of careers in medicine ... The program is an extension of Go Red ... to band together to wipe,out heart disease, their number one ...
... BeaconEquity.com announces the availability of Trade Alerts on stocks ... notes for free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts ... (NYSE: WLP ), Aetna Inc. (NYSE: ... Group Inc. (NYSE: UNH ) and Universal American ...
... studies into the causes of leukaemia, potentially leading to ... year. , Led by Dr Andrew Wei and Professor ... Hospital and Dr Louise Purton and Dr Maria Askmyr ... handful world-wide investigating the impact of the bone marrow ...
... Architect of Health Care Reform, Received More Industry ... Health insurers and pharmaceutical manufacturers contributed $5.5 million ... Senate and House of Representatives during the last ... health care reform dominated political discourse, according to ...
... Ky., March 9 VirtualHealth Technologies, Inc. (OTC Bulletin ... Envoii Healthcare, LLC has changed it,s name to Secure ... Security products. According to Jim Renfro, VHGI President "This ... effort to demonstrate our company,s commitment on growing our ...
Cached Medicine News:Health News:Top Performers in UHC 2009 Supply Chain Performance Excellence Collaborative 2Health News:The American Heart Association and Macy's Join Forces to Drive Diversity in Medicine 2Health News:The American Heart Association and Macy's Join Forces to Drive Diversity in Medicine 3Health News:Beacon Equity Issues Technical Trade Alerts on Healthcare Plan Stocks: HUM, WLP, AET, CI, UNH, UAM 2Health News:World first treatment for leukemia being developed in Australia 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 3Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 4Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 5Health News:Envoii Healthcare, LLC is now Secure eHealth, LLC 2Health News:Envoii Healthcare, LLC is now Secure eHealth, LLC 3
500L...
Inquire...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: